Skip to main content

Genedata expanding its user network

| News

Genedata expanding its user network


The Japanese biopharmaceutical firm Ajinomoto is to use the Genedata solution to accelerate its drug development processes at its site in South Korea as well. The location in China is set to follow suit in due course. Other pharmaceutical firms are also increasingly turning to the IT solution developed in Basel.

Ajinomoto is to integrate Genedata Bioprocess at its research and development locations in Japan and South Korea. The Japanese biopharmaceutical firm is using the solution developed by the Basel-based IT company Genedata, which specializes in the life sciences sector, as a central data backbone to streamline cell culture media development and production operations, including in regulated environments, further details of which can be found in a press release issued by Genedata.

Ajinomoto has been using Genedata Bioprocess in Japan for around a year now. “The platform integrates with our existing laboratory instrumentation, allowing us to evaluate huge volumes of cell culture media development data at a level of complexity that was previously unimaginable”, comments Hiroyuki Mise, General Manager Biopharma Solutions Group, Amino Acids Department at Ajinomoto, in the press release. Use of the solution is now being expanded to the teams in South Korea to facilitate cross-site projects. There are also plans to include the company’s location in China in the future.

More customers acquired

“I am delighted to see that Ajinomoto is expanding the usage of Genedata Bioprocess across its Asian development and manufacturing sites, which is how we envision our platform to be used,” says Othmar Pfannes, CEO of Genedata, headquartered in Basel.

It was only in May that Debiopharm decided to use the Genedata Profiler. It allows the Lausanne-based pharmaceutical firm to quickly convert scientific findings into therapeutic products, thereby improving the success of clinical trials. In December, Genedata announced that Icosagen Cell Factory in Estonia would be using Genedata Biologics to digitize and automate its recombinant antibody discovery services. In October 2022, the French firm Sanofi also opted to use Genedata Biologics at additional research and development sites.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.